← All organizations
Highest phase reached
Phase 3
First clinical trial
Feb 1, 2001Last known activity
Oct 20, 2021
Acquired by X-act Cologne Clinical Research GmbH on Apr 1, 2019
Timeline
1990s
- Jun 1, 1994
WiSP GmbH— Founded
2010s
- Apr 1, 2019
X-act Cologne Clinical Research GmbH— Acquired By
Drugs by trial phase (27 distinct, 14 trials)
Phase 3 (11 own, 0 via acquisition)
Phase 2 (15 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Studied for
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Gastrointestinal Stromal Tumors
- Hodgkin Disease
- Hypersensitivity
- Kidney Failure, Chronic
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Lymphoma, Non-Hodgkin
- Lymphoproliferative Disorders
- Multiple Myeloma
- Neoplasms
- Neoplasms, Plasma Cell
- Ovarian Neoplasms
- Rectal Neoplasms
- Renal Insufficiency
- Stomach Neoplasms
- Thrombocytopenia
- Urinary Bladder Neoplasms
Recent trials (14)
- NCT04891809CollaboratorPhase 2Oct 20, 2021
- NCT03171389CollaboratorPhase 2Mar 22, 2017
- NCT02560220CollaboratorPhase 1Aug 1, 2015
- NCT01397149CollaboratorPhase 1/Phase 2Oct 1, 2011
- NCT01388621Lead sponsorPhase 2Oct 1, 2011
- NCT01257360Lead sponsorPhase 2Dec 1, 2010
- NCT01234324CollaboratorPhase 2Oct 1, 2010
- NCT01374789Lead sponsorPhase 2Jul 1, 2010
- NCT01088620Lead sponsorPhase 2Apr 1, 2010
- NCT01392079CollaboratorPhase 2Feb 1, 2008
- NCT01085058Lead sponsorPhase 2/Phase 3May 1, 2003
- NCT01423032Lead sponsorPhase 2/Phase 3Sep 1, 2001
- NCT02288741Lead sponsorPhase 3Aug 1, 2001
- NCT01423695Lead sponsorPhase 2Feb 1, 2001
Details
- Founded
- Cologne, DE Jun 1, 1994
- Last known activity
- Oct 20, 2021